Unleashing the Power of Tregs
Clinical Trials for Neurodegenerative Diseases
Multiple Treg therapeutic modalities addressing neurodegenerative, autoimmune, and metabolic disease
About Coya Therapeutics
Coya Therapeutics is a clinical-stage biotechnology company focused on developing proprietary therapies to enhance the function of regulatory T cells (Tregs). Our multi-modality pipeline includes Treg-enhancing biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapy, targeting conditions where dysfunctional Tregs contribute to disease progression.
Our Clinical Programs
Explore our current clinical trial opportunities.
COYA 302
Amyotrophic Lateral Sclerosis (ALS)
ALSTARS Trial: Study of COYA 302 for the Treatment of ALS
A Phase 2 clinical trial evaluating COYA 302, an investigational Treg-enhancing combination therapy, for adults with ALS.
COYA 302
Frontotemporal Dementia (FTD)
COYA 302 for Frontotemporal Dementia (FTD)
An upcoming clinical trial evaluating COYA 302 for the treatment of Frontotemporal Dementia.
Our Science
Pioneering the research and development of new therapies to enhance the function of regulatory T cells
COYA 302 for ALS
Treg Enhancing Biologics
Combination therapy currently enrolling patients with Amyotrophic Lateral Sclerosis (ALS)
COYA 302 for FTD
Treg Enhancing Biologics
Combination therapy for Frontotemporal Dementia - FDA IND accepted January 2026